TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A post hoc analysis of a randomized trial found that older adults assigned to eat walnuts daily had total IgG concentrations about 6% higher than controls after two years. The study did not show that walnuts improved health or reduced cardiovascular risk, and the clinical meaning of the antibody difference is unknown.
A two-year analysis of the Walnuts and Healthy Aging (WAHA) trial found that older adults assigned to eat walnuts daily had total IgG levels about 6% higher than participants in a walnut-free control group. The finding concerns an immune-system biomarker, not a demonstrated health benefit: researchers said the clinical implications remain uncertain.
The analysis, published in JACC Advances, examined blood samples from 474 participants in the United States and Spain. They were part of a larger randomized trial of 708 cognitively healthy adults aged 63 to 79. Participants were assigned to a walnut-based diet or a diet that excluded walnuts for two years; the walnut group was asked to eat 30 to 60 grams daily.
Across the two study locations, total serum IgG was approximately 6% higher in the walnut group than in controls at the end of the trial, after researchers accounted for baseline levels and several participant characteristics. The difference was not statistically significant in the Spanish group when analyzed separately. Among U.S. participants, IgG was 11% higher in the walnut group than in controls.
The researchers also measured total IgM, antibodies directed at MDA-modified LDL, and MDA-LDL itself. They found no significant effect of walnut consumption on those measures. Total IgG and IgM, as well as MDA-LDL-specific IgM antibodies, fell over the two years in both groups. MDA-LDL-specific IgG antibodies and circulating MDA-LDL did not change significantly within either group.
What Higher IgG Can—and Cannot—Show
IgG is a class of antibody involved in the body’s humoral immune response. Its concentration is one measure of circulating antibodies, but a higher total level does not by itself establish that a person is better protected from infection, has less inflammation, or faces lower cardiovascular risk. The study measured a biomarker difference; it did not show that the difference led to a change in symptoms, disease, or survival.
The question matters because atherosclerosis involves plaque buildup and chronic inflammation, and immune responses to modified LDL particles are being studied for possible links to cardiovascular disease. Earlier research cited by the authors has associated higher IgG with lower cardiovascular-event risk in a particular group of people with hypertension. That association does not show that raising IgG through walnuts would prevent events, and findings for antibodies specifically targeting MDA-LDL have been mixed.
For readers, the result is a reason for further research rather than evidence to use walnuts as an immune treatment or cardiovascular prevention strategy. The trial tested a dietary assignment in selected older adults and did not establish the health consequences of the observed IgG difference.
Products Worth Considering
Oral-B iO Series 5 Rechargeable Electric Toothbrush with Travel Case, White
Fitbit Sense 2 Smartwatch – Blue Mist / Pale Gold
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black
As an affiliate, we earn on qualifying purchases.
How the WAHA Trial Tested Walnuts
The WAHA trial enrolled 708 cognitively healthy adults aged 63 to 79 in the United States and Spain. It was originally designed to assess cognitive function and retinal integrity, rather than the immune markers reported in this later analysis. The new work is described as a post hoc analysis—an examination of additional outcomes using trial data and stored samples.
Researchers tested serum collected at the start and after two years from 240 people in the walnut group and 234 controls. They used laboratory assays to measure total IgG and IgM, MDA-LDL, and antibodies targeting MDA-LDL. The analysis adjusted for factors including age, sex, smoking, study center, cholesterol, body mass index, hypertension, and diabetes.
Participants who regularly ate more than two servings of tree nuts per week were excluded from the original trial. The researchers also excluded people who regularly used certain supplements, including soy lecithin, fish oil, or flaxseed oil. Follow-up visits took place every two months to track factors such as adherence, medication use, body weight, and tolerance.
“Long-term walnut consumption was associated with total serum IgG concentrations approximately 6% higher than those of controls.”
— The study authors
What the Antibody Difference Cannot Tell Us
The analysis does not establish why total IgG was higher in the walnut group or whether that increase has any meaningful effect on health. It did not show fewer cardiovascular events, stronger protection against infections, or a change in atherosclerosis. The clinical significance of the 6% difference is unknown.
The result also varied by location: the U.S. group showed an 11% difference, while the Spanish analysis found no statistically significant intervention effect. Baseline IgG and IgM levels differed substantially between the two centers, and participant characteristics also varied. The researchers adjusted for several factors, but the center-specific results mean the overall finding should not be read as uniform across populations.
Because these immune outcomes were examined in a post hoc analysis of a trial designed for other purposes, the study offers a signal for further investigation, not a definitive test of walnuts’ effect on immunity. The available report does not establish whether the difference persists beyond two years or whether it is associated with future clinical outcomes.
Further Research on IgG and Health
The immediate next step is independent research testing whether the IgG association can be reproduced and whether it corresponds to changes in health outcomes. Studies designed in advance to measure immune markers and cardiovascular events could clarify whether the laboratory difference has practical importance.
Until such evidence is available, the study supports only a cautious conclusion: in this trial, assignment to a daily walnut diet was associated with higher total IgG after two years, while several other measured immune markers did not differ significantly from controls. Researchers have not shown that this finding changes medical guidance or establishes walnuts as a way to improve immune function.
Key Questions
What does IgG do?
IgG is a type of antibody involved in the body’s immune response. A total IgG blood measurement reflects circulating levels of that antibody class; it does not, on its own, show how well someone is protected from a particular illness.
Did walnuts improve participants’ health?
The analysis did not establish a health improvement. It found a difference in total IgG levels, but did not show that walnut consumption reduced cardiovascular events, infections, or other clinical outcomes.
How much higher was IgG in the walnut group?
Across participants in both countries, total IgG was approximately 6% higher than in controls after two years. The U.S. subgroup had an 11% difference; researchers did not detect a statistically significant effect in the Spanish subgroup.
Did walnuts affect the other immune markers?
The researchers found no significant walnut-related effect on total IgM, MDA-LDL, or antibodies targeting MDA-LDL. Some measures declined over time in both the walnut and control groups.
Does this study mean people should eat walnuts to boost immunity?
No. The study does not show that walnuts boost protection from illness or that the observed IgG difference is beneficial. It reports an association in a specific trial population, and the health meaning remains uncertain.
Source: news-medical.net
